%0 Journal Article
%T A 6-month, multicenter, open-label study of fixed dose naproxen/esomeprazole in adolescent patients with juvenile idiopathic arthritis
%A Adam Reinhardt
%A Andrew Zeft
%A Beth Gottlieb
%A Brian D. LaMoreaux
%A Daniel J. Lovell
%A Donald Goldsmith
%A Emily Von Scheven
%A Henry Naddaf
%A Jason A. Dare
%A Julie Ball
%A Lawrence Jung
%A Megan Francis-Sedlak
%A Oral Alpan
%A Ramesh Gupta
%A Rita Jerath
%A Robert J. Holt
%J Archive of "Pediatric Rheumatology Online Journal".
%D 2018
%R 10.1186/s12969-018-0260-y
%X Juvenile idiopathic arthritis (JIA) is an inflammatory arthritis of unknown etiology, which lasts for greater than 6 weeks with onset before 16 years of age. JIA is the most common chronic rheumatic disease in children. NSAIDs have been the mainstay of initial management with naproxen (NAP) being commonly used, but they may cause serious side effects such as gastric ulcers which can be reduced by concomitant administration of proton pump inhibitors, such as esomeprazole (ESO)
%K Juvenile idiopathic arthritis
%K Non-steroidal anti-inflammatory drugs (NSAIDs)
%K Naproxen
%K Esomeprazole
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6019234/